PMID

Data

Article Title

Organization

Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.

Schering-Plough Research Institute

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

University Of Montpellier

Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2.

Albert Szent-Gy£Rgyi Medical University

Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.

Msd

Oral oxytocin antagonists.

Drugmoldesign

Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.

Ligand Pharmaceuticals

 

Vasopressin trisulphide: synthesis, NMR study and affinity studies with V₁ and V₂ subtypes receptors

TBA

Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine derivatives: novel arginine vasopressin antagonists.

Central Pharmaceutical Research Institute

New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.

Université

Nanomolar-affinity, non-peptide oxytocin receptor antagonists.

Merck Research Laboratories

Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.

TBA

Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.

Merck Sharp & Dohme Research Laboratories

Orally active, nonpeptide oxytocin antagonists.

Merck Research Laboratories